Chimerix (NASDAQ:CMRX) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.33) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.09, Fidelity Earnings reports. Chimerix had a negative net margin of 1,582.64% and a negative return on equity of 34.94%. The business had revenue of $0.37 million during the quarter, compared to analyst estimates of $0.97 million.
Shares of CMRX traded down $0.17 during mid-day trading on Friday, hitting $3.32. 84,193 shares of the company traded hands, compared to its average volume of 215,341. Chimerix has a 1-year low of $3.11 and a 1-year high of $5.94. The company has a market cap of $172.41 million, a P/E ratio of -2.20 and a beta of 1.20.
Several research firms have recently issued reports on CMRX. Zacks Investment Research downgraded shares of Chimerix from a “buy” rating to a “hold” rating in a report on Tuesday, August 14th. Cowen restated a “hold” rating and set a $6.00 price objective on shares of Chimerix in a report on Thursday, October 18th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of Chimerix in a report on Friday, September 7th. One investment analyst has rated the stock with a sell rating, three have given a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company’s stock. Chimerix has an average rating of “Hold” and an average target price of $6.75.
WARNING: “Chimerix (CMRX) Releases Quarterly Earnings Results” was first reported by Baseball Daily News and is the sole property of of Baseball Daily News. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://www.baseballdailydigest.com/2018/11/10/chimerix-cmrx-releases-quarterly-earnings-results.html.
Chimerix Company Profile
Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.
Recommended Story: What do I need to know about analyst ratings?
Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.